Stopped: Sponsor's decision
This is a Phase 3, global, open-label extension (OLE) study of adjunctive GNX treatment in children and adults with TSC who previously participated in either Study 1042-TSC-3001 or Study 1042-TSC-2001
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Withdrawals and Dose-Reductions Due to AEs
Timeframe: Up to 150 Weeks
Number of Participants With Clinically Significant Changes in Vital Parameters
Timeframe: Up to 150 Weeks
Number of Participants With Clinically Significant Changes in Physical Examinations
Timeframe: Up to 150 Weeks
Number of Participants With Clinically Significant Changes in Neurological Examinations
Timeframe: Up to 150 Weeks
Number of Participants With Clinically Significant Changes in Developmental Examinations
Timeframe: Up to 150 Weeks
Number of Participants With Clinically Significant 12-lead Electrocardiogram (ECG) Findings
Timeframe: Up to 150 Weeks
Number of Participants With Clinically Significant Changes in Hematology Parameters
Timeframe: Week 1 through Week 150
Number of Participants With Clinically Significant Changes in Chemistry Parameters
Timeframe: Up to 150 Weeks
Number of Participants With Clinically Significant Changes in Urinalysis
Timeframe: Up to 150 Weeks
Number of Participants (Age Greater Than 17 Years) With Abnormal Columbia-Suicide Severity Rating Scale (C-SSRS)
Timeframe: Up to Week 52